Watson Receives FDA Approval for Generic Actos®

               Watson Receives FDA Approval for Generic Actos®

PR Newswire

PARSIPPANY, N.J., Oct. 26, 2012

PARSIPPANY, N.J., Oct. 26, 2012 /PRNewswire/ --Watson Pharmaceuticals, Inc.
(NYSE: WPI) today announced that Watson has launched a generic version of
Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after
receiving final approval today from the U.S. Food and Drug Administration
(FDA). Watson began shipping the product immediately.

On August 15, 2012, Watson announced that it had filed suit against the FDA
challenging the Agency's decision regarding Watson's entitlement to shared
exclusivity for its generic version of Actos®. Mylan Pharmaceuticals, Inc.
subsequently intervened as a defendant in the action. On October 22, 2012,
the U.S. District Court for the District of Columbia granted summary judgment
in favor of Watson and ordered the FDA to approve Watson's ANDA. Mylan
appealed the judgment to the U.S. Court of Appeals for the District of
Columbia Circuit. The Court of Appeals has denied Mylan's motion for a stay of
the judgment pending the appeal.

For the 12 months ending August 31, 2012, Actos® and its generic equivalents
had total U.S. sales of approximately $2.7 billion, according to IMS Health

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical
company. The Company is engaged in the development, manufacturing, marketing
and distribution of generic pharmaceuticals and specialized branded
pharmaceutical products focused on Urology and Women's Health. The Company is
also developing biosimilar products in Women's Health and Oncology.
Additionally, Watson distributes generic and branded pharmaceuticals through
its Anda, Inc. distribution business. Watson has operations in many of the
world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Watson's current perspective of
existing information as of the date of this release. It is important to note
that Watson's goals and expectations are not predictions of actual
performance. Actual results may differ materially from Watson's current
expectations depending upon a number of factors, risks and uncertainties
affecting Watson's business. These factors include, among others, the inherent
uncertainty associated with financial projections; the difficulty of
predicting the timing or outcome of product development efforts, including FDA
and other regulatory agency approvals and actions, if any; the impact of
competitive products and pricing; the timing and success of product launches;
the inherent uncertainty of litigation, including the pending lawsuit and
appeal related to Watson's pioglitazone product; difficulties or delays in
manufacturing; the availability and pricing of third party sourced products
and materials; successful compliance with FDA and other governmental
regulations applicable to Watson and its third party manufacturers'
facilities, products and/or businesses; changes in the laws and regulations,
including Medicare and Medicaid, affecting among other things, pricing and
reimbursement of pharmaceutical products; and such other risks and
uncertainties detailed in Watson's periodic public filings with the Securities
and Exchange Commission, including but not limited to Watson's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2012 and Watson's Annual
Report on Form 10-K for the year ended December 31, 2011. Except as expressly
required by law, Watson disclaims any intent or obligation to update these
forward-looking statements.

Actos® is a registered trademark of Takeda Chemical Industries, Ltd.


Lisa DeFrancesco
(862) 261-7152

Charlie Mayr
(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

SOURCE Watson Pharmaceuticals, Inc.

Website: http://www.watson.com
Website: PRN Photo Desk, photodesk@prnewswire.com
Press spacebar to pause and continue. Press esc to stop.